Isotretinoin
1. Pregnancy Evidence & Regulatory Labeling
FDA Pregnancy and Lactation Labeling Rule (PLLR 8.1) & EMA SmPC Section 4.6
Clinical Risk Summary
FDA Boxed Warning & Absolute Contraindication / iPLEDGE REMS Program. Isotretinoin is an extreme human teratogen. Exposure during pregnancy causes a ~35% rate of major congenital malformations (Retinoic Acid Embryopathy: craniofacial dysmorphism, microtia/anotia, micrognathia, conotruncal cardiovascular defects, thymus hypoplasia, hydrocephalus, cerebellar hypoplasia) and ~50% rate of severe neurocognitive impairment.
Human Pregnancy Experience & Clinical Studies
Extensive human surveillance documents severe multi-organ malformations in over one-third of exposed live births.
Animal Reproductive & Developmental Toxicity Data
Classic teratogen across all vertebrate species.
Clinical Considerations for Prescribers
Mandatory participation in FDA iPLEDGE program: 2 negative pregnancy tests prior to initiation, monthly negative tests, and 2 simultaneous effective forms of contraception starting 1 month before, during, and for 1 full month after discontinuation.
Placental Transfer
Crosses the placenta freely, directly perturbing neural crest cell migration and gene expression.
Regulatory Warnings & Contraindications
FDA Boxed Warning: This medication carries an official Boxed Warning regarding embryo-fetal toxicity or pregnancy-related adverse outcomes.
Strictly contraindicated in pregnant women or women who may become pregnant.
2. Lactation & Breastfeeding Safety
NIH / NLM LactMed® Database & FDA Labeling Section 8.2
Summary of Use during Lactation
Contraindicated during breastfeeding due to the potential for severe toxicity in the infant.
Drug Levels in Breast Milk & Relative Infant Dose
High lipid solubility ensures significant breast milk excretion.
Effects in Breastfed Infants & Monitored Signs
Potential for hypervitaminosis A, skeletal toxicity, and hepatic dysfunction in the infant.
Effects on Lactation & Milk Production
No data.
Alternate Medications with Established Lactation Data
4. Regulatory Source Provenance & Comparison
Direct attribution to official regulatory documents without synthesized consensus
| Regulatory Organization | Jurisdiction | Document / Framework | Effective Date | Official Source Link |
|---|---|---|---|---|
|
National Institutes of Health (NIH) / NLM
LactMed® Database (Drugs and Lactation)
|
United States / Global | evidence_monograph | 2026-08-01 | Official Record |